Clinical Trial

Mosquito-Borne Disease and Mosquito Control Vaccine

Study Description

Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine

The purpose of this study is to evaluate the safety and immunogenicity of AGS-v PLUS, a universal mosquito-borne disease and mosquito control vaccine, in healthy volunteers.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Biological - AGS-v PLUS Vaccine

Administered by subcutaneous injection

Biological - Montanide ISA-51 Adjuvant

Administered by subcutaneous injection

Biological - Alhydrogel® Adjuvant

Administered by subcutaneous injection

Biological - Saline Placebo

Administered by subcutaneous injection

Additional Information

Official Study Title

Randomized, Double-Blind, Placebo-Controlled, Single-Center, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine

Clinical Trial ID

NCT04009824

ParticipAid ID

b4xrxb